Jing Teng from 3027 Sullivan St, Lafayette, IN 47906, age 50

Resumes

Principal Research Scientist

view source

Location:

West Lafayette, IN

Industry:

Pharmaceuticals

Work:

Amri (Albany Molecular Research Inc.) Oct 2015 - Oct 2015
Senior Research Investigator, Preformulation
Aptuit May 2012 - Feb 2015
Research Investigator
Aptuit Jun 2007 - Apr 2012
Senior Scientist
Ames Laboratory 2003 - 2007
Research Assistant
Iowa State University 2001 - 2003
Research Assistant

Education:

Iowa State University 2001 - 2007
Doctorates, Doctor of Philosophy, Materials Science, Engineering Hefei University of Technology 1998 - 2001
Master of Science, Masters Hefei University of Technology 1992 - 1996
Bachelors, Bachelor of Science, Chemical Engineering

Skills:

Uv/Vis
Nmr
Characterization
Gmp
Differential Scanning Calorimetry
Tem
Materials Science
Tga
Uv/Vis Spectroscopy
Dvs
Chemistry
Nuclear Magnetic Resonance
Sem
Salt
Thermodynamics
Scanning Electron Microscopy

Languages:

English
Mandarin

Jing Teng

view source

Us Patents

Polymorphs Of Osi-906
view source
US Patent:

20130158264, Jun 20, 2013
Filed:

Jun 23, 2011
Appl. No.:

13/805402
Inventors:

Arlindo L. Castelhano - New City NY, US
David A. Enger - West Lafayette IN, US
Jason A. Hanko - West Lafayette IN, US
Josef A. Rechka - Port Jefferson NY, US
Jing Teng - West Lafayette IN, US
Yonglai Yang - West Lafayette IN, US
International Classification:

C07D 487/04
US Classification:

544350
Abstract:

Polymorphic forms of the tyrosine kinase inhibitor OSI-906, preparation, pharmaceutical compositions, and uses thereof. The invention includes methods of treating diseases such as cancer, including cancer mediated at least in part by IGF-1 R and/or IR, with the polymorphs and compositions. This Abstract is not limiting of the invention.

Formulations Of Rifaximin And Uses Thereof
view source
US Patent:

20120077835, Mar 29, 2012
Filed:

Jul 12, 2011
Appl. No.:

13/181481
Inventors:

Jon Selbo - West Lafayette IN, US
Jing Teng - West Lafayette IN, US
Mohammed A. Kabir - Cary NC, US
Pam Golden - Durham NC, US
Assignee:

SALIX PHARMACEUTICALS, LTD. - Morrisville NC
International Classification:

A61K 31/437
A61P 31/04
C07D 498/22
US Classification:

514279, 540457
Abstract:

The present invention relates to new rifaximin forms comprising solid dispersions of rifaximin, methods of making same and to their use in medicinal preparations and therapeutic methods.

Crystalline Forms Of 6-(6-Aminopyrazin-2-Yl)-N-(4-(4-(Oxetan-3-Yl)Piperazin-1-Yl)Phenyl)Imidazo[L,2-A]Pyrazin-8-Amine As Syk Inhibitors
view source
US Patent:

20230098309, Mar 30, 2023
Filed:

May 19, 2022
Appl. No.:

17/664193
Inventors:

- San Mateo CA, US
Peter C. Fung - San Mateo CA, US
Pierre Giguere - Edmonton, CA
Chiajen Lai - Livermore CA, US
Craig Stewart - Natick MA, US
Jing Teng - West Lafayette IN, US
Duong D. Tran - Edmonton, CA
Iva Trantcheva - Sonoma CA, US
Yarmuch - Sherwood Park, CA
International Classification:

C07D 487/04
Abstract:

Solid forms of the compound, 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine, and solid forms of salts or co-crystals of Compound I, were prepared and characterized:Also provided are processes of making the solid forms and methods of use thereof.

Formulations Of Rifaximin And Uses Thereof
view source
US Patent:

20200397904, Dec 24, 2020
Filed:

Jun 30, 2020
Appl. No.:

16/916421
Inventors:

- Bridgewater NJ, US
Jing Teng - West Lafayette IN, US
Mohammed A. Kabir - Cary NC, US
Pam Golden - Durham NC, US
International Classification:

A61K 47/38
C07D 498/22
A61K 9/14
A61K 9/16
A61K 9/10
A61K 9/48
A61K 9/20
A61K 31/437
A61K 47/32
Abstract:

The present invention relates to new rifaximin forms comprising solid dispersions of rifaximin, methods of making same and to their use in medicinal preparations and therapeutic methods.

Sulfonamide Compounds And Use Thereof
view source
US Patent:

20200361883, Nov 19, 2020
Filed:

Nov 28, 2018
Appl. No.:

16/768031
Inventors:

- Tokyo, JP
Jing Teng - West Lafayette IN, US
Nathan Gignac - West Lafayette IN, US
Assignee:

Taiho Pharmaceutical Co., Ltd. - Tokyo
International Classification:

C07D 271/113
Abstract:

The present disclosure relates to novel crystalline forms of sulfonamide compounds, pharmaceutical compositions containing the crystalline form compounds and methods of preparing and using the same.

Solid Forms Of A Syk Inhibitor
view source
US Patent:

20200291035, Sep 17, 2020
Filed:

Feb 20, 2020
Appl. No.:

16/796479
Inventors:

- Foster City CA, US
Peter C. Fung - San Mateo CA, US
Pierre Giguere - Edmonton, CA
Chiajen Lai - Livermore CA, US
Craig Stewart - Natick MA, US
Jing Teng - West Lafayette IN, US
Duong D. Tran - Edmonton, CA
Iva Trantcheva - Sonoma CA, US
Brian Yarmuch - Sherwood Park, CA
International Classification:

C07D 487/04
Abstract:

Solid forms of the compound, 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine, and solid forms of salts or co-crystals of Compound I, were prepared and characterized:Also provided are processes of making the solid forms and methods of use thereof.

Polymorphs Of Cocrystals Of Epigallocatechin Gallate And Caffeine
view source
US Patent:

20180289715, Oct 11, 2018
Filed:

Sep 1, 2016
Appl. No.:

15/756213
Inventors:

- West Lafayette IN, US
Jing TENG - West Lafayette IN, US
Jon SELBO - West Lafayette IN, US
International Classification:

A61K 31/522
A61K 31/353
A23L 33/105
Abstract:

Described herein are cocrystals of epigallocatechin gallate (ECGC) and caffeine, compositions comprising such cocrystals, methods of making such cocrystals, and methods of improving animal or human health by treating with such cocrystals. In particular, Form I and Form II of a 1:2 (epigallocatechin gallate to caffeine) cocrystal are described.

Novel Crystalline Form Of A Proteasome Inhibitor
view source
US Patent:

20180044356, Feb 15, 2018
Filed:

Feb 10, 2016
Appl. No.:

15/550132
Inventors:

- Cambridge MA, US
Debra Mazaik - Holliston MA, US
Eric Elliott - Watertown MA, US
Anton Peterson - Holliston MA, US
Patricia Andres - west Lafayette IN, US
Jing Teng - west Lafayette IN, US
International Classification:

C07F 5/05
A61K 31/573
A61K 31/454
A61K 31/675
A61K 31/69
A61K 31/197
Abstract:

The present disclosure relates to a novel crystalline form of a proteasome inhibitor, and to the processes for the preparation thereof. The novel crystalline form according to the disclosure may be used in the preparation of pharmaceutical compositions for the treatment of cancer.